NextCell Pharma AB

OM:NXTCL Stock Report

Market Cap: kr45.0m

NextCell Pharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Mathias Svahn

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership1.5%
Management average tenure1.1yrs
Board average tenureno data

Recent management updates

Recent updates

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Mar 09
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

Oct 07
We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

May 23
NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

Feb 01
NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Sep 21
We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

May 31
Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Feb 15
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Mathias Svahn's remuneration changed compared to NextCell Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Feb 29 2024n/an/a

-kr39m

Nov 30 2023n/an/a

-kr41m

Aug 31 2023n/an/a

-kr40m

May 31 2023n/an/a

-kr40m

Feb 28 2023n/an/a

-kr38m

Nov 30 2022n/an/a

-kr37m

Aug 31 2022n/an/a

-kr35m

May 31 2022n/an/a

-kr30m

Feb 28 2022n/an/a

-kr28m

Nov 30 2021n/an/a

-kr26m

Aug 31 2021n/an/a

-kr25m

May 31 2021n/an/a

-kr25m

Feb 28 2021n/an/a

-kr23m

Nov 30 2020n/an/a

-kr19m

Aug 31 2020n/an/a

-kr18m

May 31 2020n/an/a

-kr17m

Feb 29 2020n/an/a

-kr17m

Nov 30 2019n/an/a

-kr16m

Aug 31 2019kr984kkr984k

-kr18m

May 31 2019n/an/a

-kr17m

Feb 28 2019n/an/a

-kr15m

Nov 30 2018n/an/a

-kr16m

Compensation vs Market: Insufficient data to establish whether Mathias's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Insufficient data to compare Mathias's compensation with company performance.

CEO

Mathias Svahn (47 yo)

no data

Tenure

kr983,528

Compensation

Dr. Mathias Svahn, Ph D is Founder of NextCell Pharma AB(also known as Cellaviva AB) and serves as its Chief Executive Officer. Dr. Svahn was an Executive Director at NextCell Pharma AB.

Leadership Team

NamePositionTenureCompensationOwnership
Mathias Svahn
Founder & CEOno datakr983.53k1.48%
SEK 664.5k
Anders Essen-Möller
Chairman8.3yrsno data6.68%
SEK 3.0m
Patrik Fagerholm
Chief Financial Officer2.7yrsno datano data
Lindsay Davies
Chief Scientific Officer3.9yrsno datano data
Edvard Smith
Medical Director & Directorno datano datano data
Sofie Jansson
Head of Cellaviva1.1yrsno datano data
Karin Gillner
Head of Quality Assurance1.1yrsno datano data
Sofia Sisay
Head of Clinical Trials1.1yrsno datano data
Tacha Zi Forshell
Head of GMP Facility1.1yrsno datano data

1.1yrs

Average Tenure

46yo

Average Age

Experienced Management: NXTCL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.